Introduction
Thymic epithelial tumors (TETs) represent a heterogeneous group of rare intrathoracic malignancies that may be aggressive and difficult to treat. 1 TETs are classified according to the WHO histopathologic classification, which distinguishes thymomas from thymic carcinomas. 2 In general, thymomas are tumors with a tendency toward local progression rather than metastasis; by contrast, thymic carcinomas have a high risk of metastatic presentation at diagnosis. 3, 4 TETs have historically been staged according to the Masaoka-Koga staging system 5 ; more recently, a TNM-based system has been adopted by the American Joint Committee on Cancer/Union for International Cancer Control, 6 but the main driver of the treatment strategy remains whether surgical resection of the tumor may be achieved, as complete resection historically represents the most significant favorable prognostic factor in survival. 7, 8 Along with the management of TETs, chemotherapy and other systemic therapies may be delivered (1) in a curative-intent approach (for patients presenting with locally advanced tumor at time of diagnosis, precluding upfront complete resection to be achieved, in which case upfront, primary chemotherapy has been used both to reduce the tumor burden-possibly allowing subsequent surgery and/or radiotherapy-and to achieve prolonged disease control) 9, 10 ; (2) as systemic therapy delivered as exclusive, palliative-intent treatment of unresectable, metastatic TETs (which are more frequently thymic carcinomas than thymomas 3, 4 ), after which systemic therapy in delivered as the sole modality treatment with the objective of achieving tumor responses and improving tumor-related symptoms; or (3) as several consecutive lines of systemic therapies that may be administered when the patient presents with tumor recurrence or progression. [8] [9] [10] As no randomized or even prospective comparative study has ever been conducted to assess systemic therapy in those clinical situations, there is a paucity of data regarding the outcome of patients; ultimately, the available guidelines are characterized by low levels of evidence. 10, 11 Réseau tumeurs THYMiques et Cancer (RYTHMIC) is the nationwide network for TET in France, which was established in 2012. 12 Within the network, the management of any patient in whom a TET has been diagnosed is systematically discussed on a real-time basis at a national multidisciplinary tumor board (MTB). A database is hosted by the French Thoracic Cancer Intergroup; it prospectively collects information and follow-up for all consecutive TET patients. In this study, we took advantage of this prospective database to describe the modalities of chemotherapy and other systemic therapies for TETs and to analyze patient outcomes with regard to response and survival of patients in a real practice setting.
Methods

Study Design
RYTHMIC is a nationwide network dedicated to the management of TETs in France. It was appointed in 2012 by the French Institut National du CAncer as part of its rare cancer initiative. [11] [12] [13] The network aims at territorial coverage by 14 regional expert centers, dissemination of the highest standards for diagnosis and treatment, and promotion of collaborative research. The RYTHMIC MTB meets twice a month using a web-based conferencing system, with a minimum of three expert multidisciplinary teams discussing the management of patients; characteristics of all patients, treatments, and follow-up are prospectively collected in the network database, which is hosted by the French Thoracic Cancer Intergroup. MTB decisions are based on RYTHMIC recommendations (downloadable at www.rythmic.org/01/ images/RYTHMIC/Doc/Referentiel_RYTHMIC_2016.pdf), which are in turn based on the European Society for Medical Oncology (ESMO) clinical practice guidelines. 9 Registration of all patients in whom a TET has been diagnosed is recommended as a part of good clinical practice for oncologists. Quality control measures are implemented to ensure that decisions are applied and accurate follow-up of patients is conducted. From January 2012 to September 2015, a total of 1000 patients were enrolled, leading to the raising of 1401 questions at the MTB. 12 7%] ). As of June 2018, a total of 2600 patients had been enrolled and followed up. According to national epidemiological data, the RYTHMIC network is estimated to cover 95% of patients with a newly diagnosed TET in France. 13 
Definitions for Systemic Therapies
According to definitions and policies of the International Thymic Malignancy Interest Group (ITMIG), 9 systemic therapy for TET includes (1) primary chemotherapy delivered as induction treatment for unresectable locally advanced tumors at the time of diagnosis, with the intent of subsequent surgical resection or definitive radiotherapy; (2) exclusive systemic therapy in advanced tumors with no plan for surgery or radiotherapy (e.g., in patients with metastatic disease; and (3) systemic therapy for recurrence after surgery, radiotherapy, or disease progression after exclusive systemic therapy (multiple lines of systemic therapies may be administered for second, third, and, possibly, subsequent recurrences). In this study, we have analyzed the modalities and outcomes of systemic therapies using the framework of those definitions.
Identification of Patients
The inclusion criteria for this analysis were as follows: (1) histologically confirmed TET, (2) discussion at the RYTHMIC MTB about whether chemotherapy or other systemic therapy should be delivered, (3) administration of at least one cycle of systemic treatment, and (4) prospective assessment of response and survival. Patients were identified by using the RYTHMIC prospective database, which is hosted by the French Thoracic Cancer Intergroup. The inclusion period was from January 2012 to September 2015. Follow-up was obtained in all cases and censored on December 31, 2017.
Data Collection
The data (including patient baseline characteristics, histologic type, stage, systemic therapy regimen, dates of treatment initiation and discontinuation, and dates of progression) were collected from the a review of each patient's medical records, especially for analyses of treatment sequences.
Part of the RYTHMIC network's activity, systematic pathological review is conducted for all cases by a panel of expert pathologists on the basis of the standard WHO classification.
2 Masaoka-Koga stage was assessed according to ITMIG recommendations by using clinical, imaging, and pathological findings for resected tumors 5 ; given the period of this study, we did not use the eighth American Joint Committee on Cancer/Union for International Cancer Control TNM system. 6 Best response to systemic treatment was assessed by treating physicians according to the ITMIG recommendations adopted by the RYTHMIC/ESMO guidelines; briefly, these recommendations are as follows: (1) unidimensional tumor measurement by computed tomography scan, (2) use of the Response Evaluation Criteria in Solid Tumors (version 1.1), (3) inclusion of pleural nodules as target lesions, and (4) use of tumor thickness perpendicular to the chest wall or the mediastinum instead of the long axis for those lesions.
10,14
Statistical Analyses
All patients were included in the statistical calculations. Categorical variables were compared by using the chi-square or Student t test, and continuous variables were compared by using the Mann-Whitney nonparametric test. Survival was assessed by the Kaplan-Meier method. For patients who received primary chemotherapy, time to progression (TTP) was calculated from the date of initiation of chemotherapy to the date of relapse, with censoring at the date of last follow-up if the patient had not presented with disease progression. For patients who received exclusive systemic therapy or systemic therapy for recurrence, progression-free survival (PFS) was calculated from the date of initiation of chemotherapy to the date of progression, with censoring at the date of last follow-up if the patient had not presented with disease progression. Overall survival (OS) was calculated from initiation of systemic therapy to the date of death, with censoring at the last follow-up date if the patient was alive. Relevant parameters were studied for influence on survival by univariate analysis with use of the log-rank test and by multivariate analysis with use of a stepwise Cox proportional hazards method (entry and exit p ¼ 0.10). The differences were considered statistically significant at the 0.05 level. All analyses were performed with SPSS software (version 23.0, IBM Inc, Armonk, NY).
Results
Patients' Characteristics
A total of 236 consecutive patients for whom systemic therapy had been discussed at the RYTHMIC MTB were identified, leading to 367 questions regarding management. Ultimately, primary chemotherapy was discussed for 91 patients; exclusive systemic was discussed for 54 patients; and systemic therapy was discussed for a first, second, third, and fourth recurrence for 114 patients, 81 patients, 51 patients, and 27 patients, respectively ( Supplementary Fig. 1 ). Overall, patients received an average of 2.3 lines of systemic treatment; patients with thymoma received a higher number of lines (p ¼ 0.047).
With regard to patient characteristics, 133 patients (56%) were men and the median age at diagnosis was 56 years (range 17-88 years) ( Table 1 ). The TET histologic type was thymoma in 119 patients (50%) and thymic carcinoma in 117 (50%); virtually all patients (96%) were Masaoka-Koga stage III or IV at time of diagnosis.
Primary Chemotherapy
Primary chemotherapy was delivered to 91 patients. It consisted of PAC (cyclophosphamide, Adriamycin [doxorubicin] , and cisplatin) in 70% of cases (Fig. 1A) ; we did not identify a significant predictor of the choice of PAC versus another regimen. The objective response rate was 83% for thymoma and 75% for thymic carcinoma (Fig. 2) ; the rate of response to PAC was no different in thymoma (78%) than in thymic carcinoma (74%). Overall, 57 patients (63%) underwent surgical treatment of the tumor, with complete resection achieved in 70% of cases; 32 patients (56%) received postoperative radiotherapy. Definitive radiotherapy was administered to 21 patients (23%).
After a median follow-up of 26.6 months, the median TTP after the initiation of primary chemotherapy was 23.2 months (Fig. 3A) . At multivariate analysis, the variables associated with prolonged TTP were histologic type of thymoma versus thymic carcinoma (hazard ratio (Fig. 3B) ; sex, age, stage, histologic type, presence of autoimmune disorder, type and activity of the center, response to chemotherapy, and resection status did not significantly influence OS at multivariate analysis.
Exclusive Systemic Therapy
Exclusive systemic therapy with no intent of subsequent focal treatment was administered to 54 patients; the most frequent regimen was PAC (36 patients [67%]) (Fig. 1B) . The objective response rates were 31% for thymomas, and 37% for thymic carcinomas (p ¼ 0.743) (see Fig. 2) ; they rates were significantly higher in patients who received the PAC regimen versus others (44% versus 17%, respectively [p ¼ 0.044]).
After a median follow-up of 16.7 months, the median the PFS was 6.2 months (Fig. 3C) . At multivariate analysis, the only variable associated with prolonged PFS was tumor response (HR ¼ 0.39, 95% CI: 0.23-0.67, p ¼ 0.001). The median OS was not reached (Fig. 3D) ; no predictor of OS was identified.
Systemic Therapy for Recurrence
In our cohort, 114 patients received systemic therapy for a first tumor recurrence or progression after focal treatment or exclusive chemotherapy, respectively. A combination of carboplatin and paclitaxel was the preferred regimen; it was administered to 50 patients (44%) (Fig. 1C) 12%] ). Response and stable disease were observed in 39% and 45% of patients with thymoma and in 18% and 44% of patients with thymic carcinoma, respectively (see Fig. 2 ); responses were more frequent in patients with thymomas (p ¼ 0.016) and if a combination of carboplatin and paclitaxel was administered (p ¼ 0.036). After a median follow-up of 16.6 months, the median PFS was 7.7 months (Fig. 3E) . At multivariate analysis, the histologic type of thymoma (HR ¼ 0.39, 95% CI: 0.24-0.62, p < 0.001) and response to treatment (HR ¼ 0.32, 95% CI: 0.18-0.56, p < 0.001) were associated with higher PFS. The median OS from the first recurrence was 44.0 months (Fig. 3F) . Systemic treatment for a second recurrence and third recurrence was administered to 81 and 51 patients, respectively; the median delay after discontinuation of the previous line was 4.1 weeks. Overall, 22 patients with a second recurrence (27%) and 17 patients with a third recurrence (33%) received single-agent sunitinib (or another oral inhibitor of vascular endothelial growth factor receptor). Other options for patients with a second recurrence and patients with a third recurrence included a combination of platin and paclitaxel (20 (Fig. 1D and E) . Although responses were observed in 30% and 29% of patients with thymoma in Figure 1 . Chemotherapy and other systemic agent regimens, delivered as primary treatment (n ¼ 91) (A), exclusive treatment (n ¼ 54) (B), therapy for a first recurrence (n ¼ 114) (C), therapy for a second recurrence (n ¼ 81) (D), therapy for a third recurrence (n ¼ 51) (E), and therapy for a fourth recurrence (n ¼ 27) (F). PAC, cyclophosphamide, Adriamycin (doxorubicin), and cisplatin; VEGFR, vascular endothelial growth factor receptor; CAP, capecitabine.
the setting of second and third recurrence, the disease control rates were 90% and 86%, respectively (see Fig. 2 ); this suggests selection of patients with low progressive disease. The response rates were lower in thymic carcinomas (18% and 4%, respectively), with a higher risk of progression (38% and 30%, respectively). No variable was significantly associated with response. The median PFS and OS after treatment of a second recurrence were 6.2 and 32.1 months, respectively ( Fig. 3G and H) . The median PFS and OS after treatment of a third recurrence were 5.9 and 13.8 months, respectively ( Fig. 3I and J) . Response to treatment for a second or third recurrence was associated with more prolonged PFS (HR ¼ 0.54, 95% CI: 0.37-0.79, p < 0.001).
Only 27 patients were treated for a fourth recurrence by using sunitinib ( (Fig. 1F) . The median PFS and OS were 6.5 and 11.4 months, respectively.
Discussion
Taking advantage of the RYTHMIC network infrastructure, our analysis is to our knowledge, the first to report the efficacy of systemic treatment for advanced TETs in a prospective nationwide cohort of consecutive patients in the unique setting of systematic discussion at an expert MTB at each step of the management of patients based on clinical practice guidelines.
First, this unique process allows the analysis of data based on the actual intent of the treatment-something that had not been possible in most previously reported retrospective or prospective studies, which combined patients receiving systemic treatment with curative intent and those receiving systemic treatment with palliative intent or patients treated in various lines of treatment. [15] [16] [17] Our results clearly indicate the value of distinguishing primary chemotherapy (induction before surgical resection of definitive radiotherapy) from exclusive chemotherapy (first-line treatment for disease ineligible for focal treatment), as clinicians' expectations may differ regarding response rates, which range from 79% to 35%, respectively (see Fig. 2 ). These figures are in line with historical studies [15] [16] [17] ; however, comparisons with previous reports may be difficult, as some series were conducted before the era of the computed tomography scan and/or without review of the imaging, and of more importance, many series mixed patients in a true induction/primary/preoperative setting with patients with no intent of subsequent surgery or radiotherapy. This finding may actually be related to the higher proportion of the thymoma histologic type in the setting of locally advanced, nonmetastatic, stage III TET treated with primary chemotherapy. 4 Thymomas are known to be more sensitive to chemotherapy, which may partly be related to a lympholytic effect of cytotoxic agents and steroids in type B thymomas 9, 14, 18, 19 ; meanwhile, thymic carcinomas, which are more frequently refractory to chemotherapy, Figure 2 . Objective response rates to treatment according to histologic type: primary treatment (n ¼ 91), exclusive treatment (n ¼ 54), therapy for a first recurrence (n ¼ 114), therapy for a second recurrence (n ¼ 81), therapy for a third recurrence (n ¼ 51), and therapy for a fourth recurrence (n ¼ 27).
usually present with metastatic disease upfront, 4 leading to delivery of exclusive systemic therapy with no intent of subsequent focal treatment. Thymic carcinomas are more frequent (accounting for 50% of cases in our cohort) than in the global population of patients with TET (21% in the RYTHMIC database). 12, 13 Besides the distinction between thymoma and thymic carcinoma, metastatic TETs may present with more aggressive biological features leading to a lower sensitivity to first-intent systemic treatment, as compared with locally advanced TETs; virtually no data regarding the molecular features of advanced TETs have been made available so far, as most comprehensive genomic studies have been conducted in treatment-naive, surgically resected tumors. 20, 21 Figure 3. Outcome of patients: time-to-progression (A) and overall survival (OS) from primary chemotherapy (B); progression-free survival (PFS) (C) and OS from exclusive chemotherapy (D); PFS (E) and OS from systemic therapy for a first recurrence (F); PFS (G) and OS from systemic therapy for a second recurrence (H); and PFS (I) and OS from systemic therapy fora third recurrence (J).
Meanwhile, distinguishing first-intent (primary or exclusive) treatment from treatment of recurrences provides insight into treatment sequences and into the management of patients; whereas the PAC regimen is used upfront for most patients (70%) as primary treatment and for 67% as exclusive, first-line treatment, carboplatin and paclitaxel, capecitabine and gemcitabine, and single-agent chemotherapies are the preferred regimens for recurrences according to the phase II studies that provided the evidence for development of the ESMO clinical practice guidelines, which were then been applied in our cohort. 10, [15] [16] [17] 22 The most frequently used targeted agents in the setting of TET recurrences are angiogenesis inhibitors (mainly sunitinib, which was delivered in 12%, 27%, 34%, and 15% of cases in our cohort for a first, second, third, and fourth recurrence, respectively), suggesting that clinicians may reserve such agents for late lines of treatment after cytotoxic chemotherapy. Efficacy may actually be lower than reported in the landmark phase II studies, as previously highlighted in a previous publication from our group on a series of 28 patients, 15 of whom received sunitinib in the fourth-line setting and beyond 23 ; the reported PFS was 3.7 months, as compared with 7.2 to 8.5 months in the phase II trial. 24 Despite the 236 patients included in our analysis, our analysis identified only PAC and carboplatin-plus-paclitaxel regimens as being associated with better outcome in the setting of first-intent (primary or exclusive) or first-recurrence treatment, respectively; it failed to show any significant difference in the outcome of patients based on systemic treatment modalities in later lines of treatment.
Still, our results indicate that multiple lines of systemic therapy may be delivered beyond first-intent treatment, providing patients with an opportunity for a clinically relevant median PFS, ranging from 5.2 to 7.7 months in the setting of recurrent disease; indeed, patients presenting with TET are usually young (their median age in our cohort was 56 years) and in a good medical condition with no comorbidities. The impact of potential cumulative side effects of systemic treatments was not assessed in our study, as toxicities are not captured in the prospective RYTHMIC database; the increased use of noncytotoxic agents in late lines of treatment suggests that those aspects, especially performance status and history of hematological toxicities, were taken into account during discussions at the MTB. Ultimately, the median OS was as high as 44 months from the first recurrence in our cohort.
Objective response may represent a surrogate for PFS in patients who are not eligible for focal treatment, as suggested by the significant association identified in our cohort in the exclusive and recurrence setting. Meanwhile, clinicians' expectation should remain stable disease, which is observed in 38% to 65% of the patients in our cohort and may have some value, as tumor growth may be slow, especially in thymomas. One limitation of our study is the absence of blinded radiological review of imaging to assess objective response; still, the RYTHMIC MTB includes the review of available imaging that is shared with the multidisciplinary panel (which usually includes a thoracic radiologist) through use of a web-based conferencing system. Still, the assessment of objective response remains challenging in TETs given the frequent occurrence of pleural and mediastinal tumor targets for which standardization of measurements is debated. 14 Ultimately, as no randomized or even prospective comparative study has ever been conducted to assess systemic therapy in those clinical situations, there is a paucity of prospective data regarding the outcome of patients; major limitations of our study remain its retrospective, uncontrolled design and the fact that the treatment regimen decisions, even if made at a central MTB and on the basis of recommendations, were made on an individual basis without use of a prespecified algorithm. This may preclude comparison between treatment regimens, as patients with the best prognosis may have received more aggressive therapies. Interestingly, we did not identify any difference in treatment sequences and outcomes among the 14 centers of the network regardless of the number of new patients seen at each (<20, 20-50, or >50), which highlights the value of centralizing expertise and homogenizing patient management through the network organization of MTB.
Ultimately, our real-life data provide the landmark PFS and response rates that are needed when designing clinical trials assessing innovative agents. In our cohort, besides antiangiogenic agents, novel targeted therapies such as mechanistic target of rapamycin, phosphoinositide 3-kinase, or cyclin-dependent kinase inhibitors were received by only a handful of patients; this is related to the limited access to those agents in the clinic (through clinical trials that usually follow a basket design to treat multiple tumor types, as only a few number of trials are dedicated to TETs, 23, 25 or through off-label use). Immune checkpoint inhibitors are currently being investigated in clinical trials 26 and were not available in France when our cohort of patients for this study was established. Ultimately, the RYTHMIC nationwide MTB offers an opportunity to systematically identify patients who are potentially eligible for such clinical trials.
To conclude, our data provide a unique insight into systemic treatment strategies for advanced TETs, highlighting the value of the ITMIG definitions and policies to distinguish primary, exclusive, and recurrence settings. Meanwhile, in the setting of a rare cancer with limited opportunities for the development of randomized clinical trials, systematic discussion at an expert MTB coupled with a prospective database offers an
